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Background: The TIMI frame count (TFC) has been proposed as a
method to assess coronary blood flow. The TFC reflects coronary
flow reserve. Cardiac hypertrophy is associated with a decrease in
coronary reserve. Several factors have been shown to relate with
TFC, but the relation between left ventricular hypertrophy (LVH)
and TFC has not yet been investigated.
Aims and objectives: To determine whether LVH affects TFC.
Materials and Methods: The TFC was measured in 200 subjects
without history of myocardial infarction and significant coronary
stenosis. Determination of left ventricular mass index (LVMI) ac-
cording to the formula of Devereux was performed, and LVH was
defined by LVMI >134 g/m2 in men and >110 g/m2 in women. The
patients were divided into 2 groups according to presence of LVH:
group 1 with LVH (n ¼ 16; aged 51 ± 11 years; 8 women), and group
2 without LVH (n ¼ 18; aged 50 ±8 years; 8 women).
Results: The mean TFC in the right coronary artery (RCA) was
significantly higher in group1 (24,1 ±4,9 frames) than in group 2
(20,9 ±5,4 frames, p ¼ 0.01). The TFC in the RCA was significantly
correlated with interventricular septum thickness (r ¼ 0,36; p ¼
0,004) and left ventricular posterior wall thickness (r ¼ 0,33; p ¼
0,007), but not with LVMI (r ¼ 0.18; p ¼ 0.17). The mean TFC in the
left anterior descending (LAD) and left circumflex (Cx) arteries
were not different between the two groups. No correlation existed
between TFC in the LAD or LCx and echocardiographic
parameters.
Conclusions: Left ventricular hypertrophy has significant effect
on the TFC in the RCA but not in LAD and LCX. Therefore, studies
comparing TFC need to consider LVH.
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Background: Antiplatelet therapy with platelet P2Y12 receptor
antagonists is a cornerstone of antithrombotic treatment in pa-
tients. Since the data is largely derived from clinical trials, the
TREASURE observational study is designed to address the need to
understand the usage pattern of Ticagrelor in real life scenario in
large number of ACS patients in India. To our knowledge, it will be
largest ever antiplatelet agent related observational study in real
world scenario in India.
Objectives: To describe the usage pattern of Ticagrelor in various
ACS patient population who undergo either PCI, CABG or medical
management in a real-life setting from 60 different centers in
India.
Methods: This is an observational, multi-centric, prospective
study. Study proposes to include 3000 subjects from 60 centres
across India. Key inclusion Criteria would be provision of subject
informed consent and Patients who had been hospitalized for ACS
and are on ticagrelor on discharge or on Ticagrelor therapy for 
1month will be enrolled in the study and followed up for a period
of 12 months. Demographic data, Diagnosis (type of ACS), Man-
agement of ACS, Laboratory Investigations, relevant history,
physical examination will be collated.
Results: Study is expected to fill a significant gap exists in our
knowledge to understand the usage pattern of Ticagrelor in real
life scenario in large number of ACS patients in India. The aim of
this national study is to understand the usage pattern (including
the duration of treatment) of Ticagrelor in various ACS patient
population undergoing PCI, CABG or medical management in a
real-life setting in India.
Moreover, patients with various risk factors [i.e. elderly pa-
tients, diabetes, renal impairment, smoking, GRACE risk score)
and their association with ACS and Ticagrelor usage will be
measured. Study also intends to record any clinical event (CV
event, Bleeding etc) during the follow up period of the study.
Conclusion: The multicenter national study will allow generating
real life evidence by involving patients from different geographies
and healthcare systems in India. The study is intended to provide
useful evidence of the ticagrelor usage in variety of ACS patients
in actual hospital settings. Along with the PLATO study result; this
data will be extremely useful to optimize ACS management in
India in order to save more lives.
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Background: Primary percutaneous coronary intervention (PCI)
is the treatment of choice for patients presenting with acute ST-
segment elevation myocardial infarction (STEMI). However, if
catheterization facilities are not immediately available (e.g.
countries like India) the effectiveness of PCI can be affected by
delays in transfer. Evidence suggests that antiplatelet therapy
administered early, preferably in the ambulance during transfer,
may provide better and earlier perfusion. Ticagrelor, a direct
platelet P2Y12 receptor inhibitor, is indicated for themanagement
of patients with acute coronary syndromes. In India, a large scale
Kerala ACS registry, found big time delay between ACS (Acute
Coronary Patients) symptom and PCI. In this scenario, it was
important to evaluate implications of ATLANTIC (Administration
of Ticagrelor in the cath Lab or in the Ambulance for New ST
elevation myocardial Infarction to open the Coronary artery)
study in Indian scenario. This analysis is imperative in the view of
the fact that the latest European Society of Cardiology (ESC) 2014
myocardial revascularization guidelines recommended P2Y12
inhibitors to be given at first medical context for patient under-
going primary PCI.
Aim: To evaluate whether earlier, in-ambulance or administration
of Ticagrelor could safely improve coronary reperfusion in pa-
tients with STEMI transferred for PCI.
Methods: ATLANTIC is an international,multicenter, randomized,
double-blind study involving 1862 patients with ongoing STEMI of
less than 6 hours duration, comparing pre-hospital (in the
ambulance) versus in-hospital (in the catheterization laboratory)
treatment with Ticagrelor. The co-primary end points were the
proportion of patients who did not have a 70% or greater resolu-
tion of ST-segment elevation before percutaneous coronary
intervention (PCI) and the proportion of patients who did not have
Thrombolysis in Myocardial Infarction flow grade 3 in the infarct-
related artery at initial angiography. Secondary end points
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